Posts
September 10 2019
Arcadia Biosciences, Inc. announced the closing of their Registered Direct offering in the amount of $10,000,013. EG&S acted as counsel to the Placement Agent.
September 09 2019
Capstone Turbine Corporation announced the closing of their Registered Direct offering in the amount of $5,100,000. EG&S acted as counsel to the Placement Agent.
September 04 2019
OncoCyte Corporation (“OncoCyte”) announced that it entered into a definitive agreement to acquire a 25% interest in Razor Genomics Inc. (“Razor”), with the right to acquire the remainder of Razor thereafter (and OncoCyte is obligated to do so upon certain milestones being reached by Razor). On September 30, 2019, OncoCyte closed its initial investment in Razor and acquired shares of Razor preferred stock representing 25% of the outstanding equity of Razor. EGS acted as counsel to OncoCyte.
September 04 2019
PolyPid Ltd., a clinical-stage biopharmaceutical company in Israel, conducted the final closing of its Series E-1 preferred share private placement offering which raised gross proceeds of $50,000,000. EG&S acted as counsel to National Securities Corporation, the U.S. placement agent for the offering.
August 27 2019
Seelos Therapeutics, Inc. announced the closing of their Registered Direct offering in the amount of $6,712,500. EG&S acted as counsel to the Placement Agent.
August 19 2019
Delcath Systems Inc. announced the closing of their PIPE offering in the amount of $9,510,434. EG&S acted as counsel to the Placement Agent.
August 14 2019
DelMar Pharmaceuticals, Inc. announced the closing of its underwritten public offering in the amount of $6,800,000. EG&S acted as counsel to Maxim Group LLC, the book-running manager in the offering.
August 14 2019
Social Reality, Inc. announced the closing of their Registered Direct offering in the amount of $5,490,000. EG&S acted as counsel to the Placement Agent.